Promyelocytic leukemia protein: an atherosclerosis suppressor protein?
PML
SUMOlyation
Vascular smooth muscle cell
atherosclerosis
Journal
Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731
Informations de publication
Date de publication:
16 07 2021
16 07 2021
Historique:
received:
09
04
2021
revised:
26
05
2021
accepted:
28
05
2021
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
12
11
2021
Statut:
ppublish
Résumé
As many as 70% of cells in atherosclerotic plaque are vascular smooth muscle cell (VSMC) in origin, and pathways and proteins which regulate VSMC migration, proliferation, and phenotype modulation represent novel targets for rational drug design to reduce atherosclerotic vascular disease. In this volume of Clinical Science, Karle et al. demonstrate that tumor suppressor, promyelocytic leukemia protein (PML) plays an important role in regulation of VSMC phenotype and response to inflammatory stimuli (Clin Sci (2021) 135(7), 887-905; DOI: 10.1042/CS20201399). This important work demonstrates that PML, previously unrecognized as a participant in development of atherosclerosis, may represent a novel target for anti-atherosclerotic therapeutic modalities.
Identifiants
pubmed: 34192313
pii: 229126
doi: 10.1042/CS20210314
doi:
Substances chimiques
Promyelocytic Leukemia Protein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
1557-1561Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.